Options for our younger 'members':
Dewi here:
Glacial progress:
In December 2021, the U.S. Food and Drug Administration (FDA) approved Cosentyx® (secukinumab) for the treatment of active psoriatic arthritis (PsA) in patients 2 years and older.
This approval is based on findings from the Phase 3 JUNIPERA study, which demonstrated that children and adolescents ages 2 to 17 years old showed an 85% reduction in the risk of flare versus placebo.
Cosentyx® is administered as a subcutaneous injection by a pre-filled syringe.
As always
, thanks for sharing and raising awareness!! Jill, Team Member Well at the end of the day the more of us that raise awareness especially with our Drs / specialists, the better the chance of improved management, amelioration, regression and or abeyance.
So true,
! -Catherine, Community Moderator
